ロード中...
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the con...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Landes Bioscience
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3489759/ https://ncbi.nlm.nih.gov/pubmed/23162771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20368 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|